Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testingLisa R. Susswein, Wendy K. Chung, Erica Vaccari et al.|Genetics in Medicine|2015Cited by 292
Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel TestingJessica L. Mester, Kathleen S. Hruska, Sarah A. Jackson et al.|Journal of Molecular Diagnostics|2019Cited by 23
PD35-07 PROSTATE CANCER RISKS IN MALE BRCA1/2 PATHOGENIC VARIANT CARRIERSSusan Hiraki, Rachel T. Klein, Lance Grau et al.|The Journal of Urology|2019Cited by 0